Comprehensive Gene Panel for Cancer Predisposition Test Cost & Procedure

Using the same Formalin-Fixed Paraffin-Embedded (FFPE) tumor sample (in the case of solid tumors) and blood or bone marrow aspirate sample, the Comprehensive Tumor Gene Panel is an all-encompassing Next-Generation Sequencing (NGS) test that looks for DNA and RNA variants (gene re-arrangements / gene fusions) (in case of leukemias or blood cancers).

Prevalence

• Globocan statistics from 2018 show that 2.25 million people were affected by cancer.
• It is known that this figure increases by 1.15 million each year.
• Males have a 9.81% chance of getting cancer before they turn 75, while females have a 9.42% chance.
• Males are more likely to develop cancers of the lip, oral cavity, cervix, stomach, colon, and esophagus than females are to develop cancers of the breast, lip, oral cavity, cervix, lung, and stomach (in descending order).

Why is the test necessary?

Provides a precise and affordable way to find 175 gene mutations, fusions, and amplifications connected to the responsiveness or resistance to particularly targeted medicines in various cancer types.

Allows for the selection of the most targeted treatment for each patient with any type of cancer-based on their genomic profile.

Aids in determining the prognosis and directing treatment for patients both early on (at the time of diagnosis) and when the disease progresses or recurs.

Who needs testing?

The best candidates for this test can be identified by treating oncologists, who can then recommend these individuals for testing.

Why did MedGenome?

• Strict quality control procedures following worldwide clinical laboratory practice recommendations, such as CAP, at all stages of sample processing, data gathering, and analysis to ensure very exact and accurate results.
• Well-trained clinical scientists/genome analysts and cancer genome specialists perform the high throughput NGS data processing, curation, and interpretation of the mutations and fusions.
• Clinically significant modifications and their interpretations are provided in the report. Their connections to pharmacological effectiveness Recommended targeted treatments/possible resistance mechanisms the prognosis and current open clinical studies
• Large clinical studies that provide corroborating medical data to support oncologists' treatment decisions throughout the whole spectrum of cancer management, including diagnosis, targeted therapy, surveillance, and recurrence

International guidelines from organizations like ASCO, AMP, CAP, NCCN, and ESMO constitute the foundation for clinical reporting and interpretations.

The test has been internally tested, and the mean sequencing Over 100 clinical samples, reference standards, and cell lines are covered by a panel with a depth of >/= 250x.

The following list of SNVs, Short InDels, and fusions' sensitivity, specificity, and accuracy